Table 1.
Baseline characteristics of patients with and without DFR ≥1 year at any time point
| sDFR | No sDFR | |||
|---|---|---|---|---|
| BeSt study | N | N=107 | N=362 | P value |
| Age, mean (SD)† | 469 | 54.6 (14.2) | 54.0 (13.5) | 0.676 |
| Gender female, n (%)§ | 469 | 56 (52.3) | 257 (71.0) | <0.001 |
| Smoking, n (%)§ | 466 | 33 (30.8) | 133 (37.1) | 0.239 |
| BMI, mean (SD)† | 469 | 25.3 (3.18) | 26.1 (4.23) | 0.069 |
| Symptom duration (weeks), median (IQR)‡ | 468 | 20.7 (11.7; 40.0) | 23.3 (14.1; 53.7) | 0.049 |
| RF-positive, n (%)§ | 469 | 56 (52.3) | 247 (68.2) | 0.003 |
| ACPA-positive, n (%)§ | 459 | 45 (42.1) | 240 (68.2) | <0.001 |
| DAS, mean (SD)† | 469 | 4.25 (0.87) | 4.47 (0.86) | 0.019 |
| HAQ, mean (SD)† | 469 | 1.20 (0.67) | 1.42 (0.66) | 0.002 |
| Initial monotherapy, n (%)§ | 469 | 53 (49.5) | 190 (47.5) | 0.713 |
| IMPROVED study | N=110 | N=311 | ||
| Age, mean (SD)† | 421 | 52.0 (13.2) | 51.9 (12.5) | 0.936 |
| Gender female, n (%)§ | 421 | 70 (63.6) | 221 (71.1) | 0.147 |
| Smoking, n (%)§ | 418 | 29 (26.6) | 99 (32.0) | 0.290 |
| BMI, mean (SD)† | 409 | 25.3 (3.69) | 26.1 (4.59) | 0.100 |
| Symptom duration (weeks), median (IQR)‡ | 420 | 15.0 (8.0; 27.0) | 20.0 (9.0; 38.0) | 0.061 |
| RF-positive, n (%)§ | 404 | 71 (67.0) | 216 (72.5) | 0.283 |
| ACPA-positive, n (%)§ | 418 | 58 (53.2) | 231 (74.8) | <0.001 |
| DAS, mean (SD)† | 421 | 3.21 (0.91) | 3.38 (0.93) | 0.117 |
| HAQ, mean (SD)† | 416 | 1.16 (0.69) | 1.18 (0.67) | 0.891 |
| Initial monotherapy* | - | - | - | - |
*In the IMPROVED study, all patients received initial combination therapy.
†
Student’s t-test was applied (parametric data).
‡Mann–Whitney U test was applied (non-parametric data).
§Pearson χ2 test was applied (binary data).
ACPA, anti-citrullinated protein antibody; BMI, body mass index; DAS, Disease Activity Score; DFR, drug-free remission; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; sDFR, sustained drug-free remission.